^
    Back
    Association details:
    Biomarker:PIK3CA mutation
    Cancer:Solid Tumor
    Drug:vevorisertib (ARQ 751) (pan-AKT inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001)

    Excerpt:
    ...Documented AKT genetic alterations or known actionable PIK3CA/PTEN mutations by genetic testing • Participants with tumors with PTEN []/PTEN loss-of-function mutations are...
    Trial ID:
    MK-4440-001
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer
    Title:

    Phase 1b study of pan-AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN-mutated advanced solid tumors

    Published date:
    03/27/2023
    Excerpt:
    Vevorisertib alone or with paclitaxel or fulvestrant had a manageable safety profile, and vevorisertib alone or with paclitaxel had minimal to modest antitumor activity in this patient population with PIK3CA/AKT/PTEN-mutated advanced solid tumors.
    Secondary therapy:
    fulvestrant; paclitaxel
    DOI:
    10.1002/cncr.34733
    Trial ID:
    MK-4440-001